|
Events
12-14 October 2008
16th Annual BioPartnering Europe
QEII Conference Centre – London, UK
Dr Paul McCubbin, Head of Business Development, and Lee Holmes, Senior Business Development Executive, BTG, hosting open house booth
More Information »Come and meet BTG on Monday, 13 October from 10:00 am in Open House Booth P
|
23-24 October 2008
DIA Project Management Excellence in Life Sciences
Grand Hotel Union - 1000 Ljubljana, Slovenia
Dr Russell Hagan, Head of Research and Development, BTG, presenting
More Information »Russell Hagan will present on Change Management on Friday, 24 October at 2:00 pm
|
3-5 November 2008
Therapeutic Area Partnerships
Loews Philadelphia Hotel – Philadelphia, Pennsylvania, USA
Dr Russell Hagan, Head of Research and Development, BTG, participating in neuroscience roundtable
|
6-9 November 2008
American College of Phlebology 22nd Annual Congress
Marco Island Marriott Resort & Spa – Marco Island, Florida, USA
BTG presenting three oral presentations and two posters
More Information »Presentions are as follows:
- Kathleen Gibson, MD, Principal Investigator, Lake Washington Vascular,
will present Proprietary Polidocanol Endovenous Microfoam (PEM) Bubble Embolization Does Not Cause Cerebral Injury (Paper #39) on Friday, 7 November 2008, 9:10-9:20 am
Janet E. Rush, MD, Head of Medical & Regulatory Affairs, US, BTG, will present Neurological and Visual Symptoms Following Treatment of the Great Saphenous Veins with Two Formulations of Polidocanol Endovenous Microfoam (PEM) (Paper#38) on Friday, 7 November 2008 10:10-10:20 am
David Wright, MB, FRCS, Vice President, Medical Affairs, BTG, will present A Single-Center Pilot Study of Polidocanol Endovenoous Microfoam (PEM) Treatment to Evaluate Presence and Durability of Gas Emboli Using Echocardiography (Paper #37) on Friday, 7 November 2008 at 11:05-11:15 am
Gregory Suplick, Vice President, Clinical Development, BTG, will present two posters entitled: Patient Recruitment Strategies and Referrals Associated with a Multicenter Phase II Study of Patients with GSV Incompetence and Patient Pre-Qualification Tools Used to Recruit Patients for a Multicenter Phase II Study of Patients with GSV Incompetence
|
10-11 December 2008
Drug Repurposing Strategies
Marriott Courtyard Philadelphia – Philadelphia, Pennsylvania, USA
Dr Thomas Logan, Vice President, Business and Product Development, BTG, presenting
More Information »Dr Logan will present Case Study: A Repositioning Strategy for the Discovery and Development of a Potential First-in-Class Drug for the Treatment of Obstructive Sleep Apnea
|
|
|